
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145811610.1021/acsomega.8b02298ArticleMicrowave-Assisted aza-Friedel–Crafts
Arylation of N-Acyliminium Ions: Expedient
Access to 4-Aryl 3,4-Dihydroquinazolinones Sawant Rajiv
T. †Stevens Marc Y. ‡Odell Luke R. *Department of Medicinal Chemistry,
Uppsala Biomedical Center, Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden* E-mail: luke.odell@ilk.uu.se.29 10 2018 31 10 2018 3 10 14258 14265 06 09 2018 12 10 2018 Copyright © 2018 American Chemical Society2018American Chemical SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

A one-pot
microwave-assisted aza-Friedel–Crafts
arylation of N-acyliminium ions, generated in situ
from o-formyl carbamates and different amines, is
reported. This metal-free protocol provides rapid access to diverse
4-aryl 3,4-dihydroquinazolinones in excellent yield without any aqueous
workup. A solvent-directed process for the selective aza-Friedel–Crafts arylation of electron-rich aryl/heteroaryl/butenyl-tethered N-acyliminium ions is also described.

document-id-old-9ao8b02298document-id-new-14ao-2018-02298xccc-price
==== Body
Introduction
N-Acyliminium
ions1−5 are versatile electrophiles that provide direct access to α-substituted
amino derivatives via the intra- or intermolecular addition of various
nucleophiles. In particular, in situ-generated N-acyliminium
ions have been widely exploited in the synthesis of bioactive nitrogen-containing
heterocycles, especially in the preparation of alkaloid natural products.1,2,6,7 Accordingly,
the development of rapid, convenient, and high-yielding protocols
for the selective intra- or intermolecular nucleophilic addition to
cyclic N-acyliminium ions remains a field of considerable
interest.8−11 The C4-substituted quinazolinone framework is known to exhibit a
wide range of biological properties. For example, SM-15811 is a potent
Na+/Ca2+ exchanger inhibitor,12−14 proquazone
is an anti-inflammatory drug,15,16 and 4-disubstituted
3,4-dihydroquinazolinones are T-type channel selective calcium blockers
with in vivo central nervous system efficacy in epilepsy and tremor
models17,18 (Figure 1). Finally, the 3,4-dihydroquinazolinones DPC 961 and
DPC 083 and related analogs are potent human immunodeficiency virus
non-nucleoside reverse transcriptase inhibitors.19,20

Figure 1 Structures
of pharmaceutically important 4-aryl quinazolinones.

The known methods for the synthesis of 4-aryl substituted
3,4-dihydroquinazolinones
include a two-step condensation of aldehyde, urea, and carboxylic
acid,21 and a three-step synthesis from o-amino acetophenones12−14,17,18 and the organocatalytic asymmetric synthesis
of trifluoromethyl 3,4-dihydroquinazolinones based on the aza-Friedel–Crafts reaction of indoles with cyclic N-acylketimines using a chiral phosphoric acid catalyst.22 Xie and co-workers reported the enantioselective aza-Friedel–Crafts reaction of naphthols/phenols
with cyclic N-acylketimines using a chiral quinine-squaramide
catalyst.23 Despite these elegant approaches,
the existing methods require either lengthy reaction sequences or
isolation of cyclic N-acylketimines, which limits
their utility in the generation of diverse 3,4-dihydroquinazolinone
libraries.

During the preparation of this manuscript, Chandrasekharam
and
co-workers reported a water-mediated multicomponent synthesis of 4-aryl
substituted 3,4-dihydroquinazolinones under conventional heating.24 However, it is important to highlight that the
use of water as a reaction medium demanded long reaction times, and,
in many cases, chromatographic purification was required, both of
which detract from its appeal as a green protocol. Moreover, the scope
of this method is restricted to indole and mono-functional amine nucleophiles,
limiting its utility in library generation. In this context, an environmentally
benign and expedient method for the rapid synthesis of 4-aryl 3,4-dihydroquinazolinone
libraries is highly desirable.

As part of our ongoing research
program, we recently reported a
highly efficient solvent-directed diversity-oriented synthesis of
skeletally diverse 3,4-dihydroquinazolinones scaffold libraries based
on N-acyliminium ion chemistry under environmentally
benign reaction conditions.25−29 Our recent findings demonstrated that the intramolecular cyclization
of aryl/heteroaryl tethered nucleophiles with N-acyliminium
ions27 leads to the formation of 3,4-dihydroquinazolinone-embedded
polyheterocycles (Scheme 1). With the aim of developing an expedient approach to 4-aryl/heteroaryl
3,4-dihydroquinazolinones, we were encouraged to investigate the intermolecular
functionalization of N-acyliminium ions (I) with indoles and arenes to produce 4-aryl 3,4-dihydroquinazolinone
scaffold libraries based on a cascade imine/cyclization/aza-Friedel–Crafts reaction sequence. Herein, we present one-pot
microwave-assisted metal-free sequential N-acyliminium
ion/aza-Friedel–Crafts arylation that provides
rapid access to 4-aryl/heteroaryl 3,4-dihydroquinazolinones from readily
available precursors (Scheme 1).

Scheme 1 Proposed Reaction Sequence for the aza-Friedel–Crafts
Arylation of N-Acyliminium Ions
Results and Discussion
We started
our investigation by optimization of the reaction conditions
for the aza-Friedel–Crafts arylation of the N-acyliminium ion generated in situ from o-formyl carbamate 1a and NH4OAc 2a (Scheme 2). We were
pleased to observe that the reaction proceeded in either AcOH or EtOH/AcOH
as the solvent. The reaction between o-formyl carbamate 1a and NH4OAc 2a (2 equiv) in AcOH
under microwave heating at 130 °C for 10 min provided N-acyliminium ion intermediate Ia (confirmed
by liquid chromatography/mass spectrometry (LC/MS)), which upon subsequent
treatment with indole 3a (1.3 equiv) and an additional
20 min of heating at 130 °C produced 4-indolyl 3,4-dihydroquinazolinone 4a in excellent yield (95%). Similarly, the two-step reaction
sequence in EtOH/AcOH (9:1) afforded dihydroquinazolinone 4a in a slightly reduced yield (91%) under optimal protic solvent/Brønsted
acid combinations (Scheme 2).

Scheme 2 Optimization Studies for the aza-Friedel–Crafts
Arylation of an N-Acyliminium Ion
With the optimized reaction conditions in hand,
we first explored
the scope of the aza-Friedel–Crafts arylation
of different cyclic N-acyliminium ions generated
in situ from o-formyl carbamates 1b–1h and NH4OAc 2a with indole 3a in AcOH (Scheme 3). N-Acyliminium ions 1b–1h derived from aldehydes 1b–1h containing electron-donating/withdrawing and halogen substituents
reacted smoothly with indole to afford the corresponding 4-indolyl
3,4-dihydroquinazolinones 4b–4f in
good to excellent yields (86–92%). The introduction of an o-substituent and N-1-benzyl substituent
was also well-tolerated, giving 3,4-dihydroquinazolinones 4g and 4h in good yield. Next, the scope of the indole
nucleophile was explored and indole derivatives containing electron-donating/withdrawing,
and halogen substituents furnished the corresponding 4-indolyl 3,4-dihydroquinazolinones 4i, 4j, and 4n in good to excellent
yield (83–92%). Sterically hindered o-substituted
indoles reacted smoothly, producing 3,4-dihydroquinazolinones 4k–4m in good to excellent yield. The
protocol also worked well with N-methylindole and
7-azaindole to afford 3,4-dihydroquinazolinones 4o and 4p in 84 and 90% yield, respectively (Scheme 3).

Scheme 3 Scope of aza-Friedel–Crafts
Arylation of N-Acyliminium Ions with Indoles
Isolated yield. All reactions
were performed with 1 equiv o-formyl carbamate (1b–1h), 2 equiv NH4OAc (2a) in 1 mL AcOH, 130 °C, MW, 10 min, and then 1.3 equiv
indole (3a–3i) 130 °C, MW, 20–30
min.

Next, to further expand the scope and
applicability of microwave-assisted aza-Friedel–Crafts
arylation of N-acyliminium ions, we investigated
the effect of varying the arene
and amine components (Scheme 4). Our protocol tolerated a wide range of amine nucleophiles,
affording the corresponding 3,4-dihydroquinazolinone in up to 95%
yield. Primary alkyl amines such as benzylamine 2a and
2-thiophenemethylamine 2b worked well to afford N-3-functionalized 3,4-dihydroquinazolinones 6a, 6b in excellent yields (>94%). A one-step three-component
reaction between aldehyde 1a, benzylamine 2b, and indole 3a afforded 6a in reduced
yield (85%) confirming that the two-step sequential approach is preferable. N-Acyliminium ions also reacted smoothly with 1,3-dimethoxybenzene 5a to produce 4-aryl 3,4-dihydroquinazolinones 6c–6e in moderate to good yields. It is important
to highlight that the branched amine N-methyl 4-amino
piperidine 2d was efficiently transformed into 6e, an analog of SM-15811 in satisfactory yield. Finally, m-cresol 5b underwent chemoselective C-functionalization
to produce 6f in 52% yield (Scheme 4).

Scheme 4 Scope of aza-Friedel–Crafts
Arylation of N-Acyliminium Ions with Arenes,
Isolated
yield. Unless otherwise
stated, reactions were performed with 1 equiv o-formyl
carbamate (1b–1h), 2 equiv NH4OAc (2a) and 1.3 equiv amine (2b–2d) in 1 mL AcOH, 130 °C, MW, 10 min, and
then 1.3 equiv Nu (3a/5a/5b) 130 °C, MW, 20–30 min.

One-step reaction in AcOH, MW, 130 °C, 20 min.

Next, we sought to expand the scope of the selective
cascade arylation
reaction using challenging amine nucleophiles bearing pendant electron-rich
aryl/alkenyl moieties (2e–2j, Scheme 5). Gratifyingly,
electron-rich aryl/heteroaryl/butenyl-tethered N-acyliminium
ions were generated in situ from o-formyl carbamate
and amines 2e–2h in EtOH/AcOH (9:1)
and reacted smoothly with indole 3a to afford N-3-aryl/heteroaryl/butenyl-tethered 4-aryl 3,4-dihydroquinazolinones 7a–7d in excellent yield (Scheme 5). However, with indole tethered N-acyliminium ions, intramolecular aza-Friedel–Crafts
cyclization was more favored under the optimized reaction conditions.
The N-acyliminium ion derived from 4-aminomethyl
indole 2i gave 7e in 36% yield along with
the polycyclic product 7e′, whereas the tryptamine
derivative gave only traces of 7f (Scheme 5). It is important to highlight that by changing
the solvent composition the reaction can be paused at the N-acyliminium ion stage, followed by selective functionalization
at the C-4 position with an external indole nucleophile, despite the
presence of a pendant electron-rich aryl, thiophene, indole, or alkene
nucleophile. Thus, the two-step protocol using a minimum of acetic
acid can effectively suppress competing intramolecular aza-Friedel–Crafts27 and aza-Prins cyclization28 reactions, allowing
the selective C-4 functionalization by an indole nucleophile.

Scheme 5 Solvent-Directed Selective 4-Arylation of Aryl/Alkenyl Tethered N-Acyliminium Ions,
Isolated yield. All reactions
were performed with 1 equiv o-formyl carbamate (1a), 1.3 equiv amine (2e–2j) in 1 mL EtOH/AcOH (9:1), 130 °C, MW, 10 min, and then 1.5
equiv Nu (3a) 130 °C, MW, 20 min.

Product not isolated.

Conclusions
In conclusion, we have developed a highly
efficient, metal-free
microwave-assisted aza-Friedel–Crafts arylation
of N-acyliminium ions. The solvent-directed selective aza-Friedel–Crafts arylation of challenging aryl/heteroaryl/butenyl-tethered N-acyliminium ions was achieved to produce 4-aryl 3,4-dihydroquinazolinones.
This protocol offers a rapid and direct approach to generate polyfunctionalized
4-aryl 3,4-dihydroquinazolinone libraries in excellent yields under
environmentally benign reaction conditions and in a short reaction
time. Moreover, the protocols utilize readily available and stable o-formyl carbamate precursors and are compatible with a
broad scope of amine and aryl/heteroaryl nucleophiles. Further investigations
to expand the scope of this approach and explore the biological activity
of these compounds are underway in our laboratory.

Experimental
Section
All reagents and solvents were obtained from commercial
suppliers
and used without further purification. The yields stated refer to
homogenous and spectroscopically pure isolated material. Thin layer
chromatography (TLC, 0.25 mm E. Merck silica plates, 60F-254) was
used to assess reaction progress and the plates were visualized with
254 nm UV light. Silica gel chromatography was performed using E.
Merck silica gel (60 Å pore size, particle size 40–63
nm). 1H NMR spectra were recorded at 400 MHz and 13C NMR spectra at 100 MHz. The chemical shifts for 1H NMR
and 13C NMR were referenced to tetramethylsilane via residual
solvent signals (1H, CDCl3 at 7.26 ppm; 13C, CDCl3 at 77.16 ppm; 1H, DMSO-d6 at 2.45 ppm; 13C, DMSO-d6 at 39.43 ppm; 1H, CD3OD at 3.31 ppm; and 13C, CD3OD at 49.0 ppm).
Microwave reactions were performed in an Initiator single mode reactor
producing controlled irradiation at 2450 MHz and the temperature was
monitored using the built-in online IR sensor. LC/MS was performed
on an instrument equipped with a CP-Sil 8 CB capillary column (50
× 3.0 mm2, particle size 2.6 μm, pore size 100
Å) operating at an ionization potential of 70 eV using a CH3CN/H2O gradient (0.05% HCOOH). High-resolution
mass values were determined using a 7-T hybrid ion trap and a time
of flight detector and an electrospray ionization source. All reactions
were performed in sealed Pyrex microwave-transparent process vials
designed for 0.5–2 mL reaction volumes, unless otherwise stated.

Preparation
of o-Formyl Carbamates
The required known
compounds 1a–1h were prepared from
the corresponding amino alcohols following the
literature procedure.25,26

General Procedure A
One-Pot,
Two-Step Preparation of 4-Aryl 3,4-Dihydroquinazolinones
(4a–4p and 6a–6f) Exemplified by 4a
A 0.5–2
mL Pyrex process vial was charged with aldehyde 1a (40
mg, 224 μmol), NH4OAc 2a (34 mg, 448
μmol), and acetic acid (1 mL). The vial was sealed and subjected
to microwave irradiation at 130 °C for 10 min, after which indole
(3a, 34 mg, 290 μmol) was added. The vial was re-sealed
and heated by microwave at 130 °C for 20 min, and thereafter
the reaction mixture was concentrated in vacuo. Silica gel chromatography
(2–5% MeOH in dichloromethane (DCM) or 30–85% EtOAc
in n-pentane) provided the title compound as a white
solid (56 mg, 95%).

General Procedure B
One-Pot, Two-Step Preparation
of 4-Aryl 3,4-Dihydroquinazolinones
(7a–7e) Exemplified by 7b
A 0.5–2 mL Pyrex process vial was charged with aldehyde 1a (40 mg, 224 μmol), amine 2f (53 mg,
290 μmol), and ethanol/acetic acid (9:1, 1 mL). The vial was
sealed and subjected to microwave irradiation at 130 °C for 10
min, after which indole (3a, 39 mg, 334 μmol) was
added. The vial was re-sealed and heated by microwave at 130 °C
for 20 min, and thereafter the reaction mixture was concentrated in
vacuo. Silica gel chromatography (2–5% MeOH in DCM or 55–70%
EtOAc in n-pentane) provided the title compound as
a white solid (85 mg, 90%).

4-(1H-Indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4a)24
Prepared following the general procedure (A), starting
from aldehyde 1a (40 mg, 224 μmol), amine 2a (34 mg, 448 μmol), and nucleophile 3a (34 mg, 290 μmol). Yield: 56 mg (95%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 10.99–10.90
(m, 1H), 9.27–9.22 (m, 1H), 7.50 (d, J = 7.9
Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.18–7.14
(m, 2H), 7.11–7.02 (m, 2H), 6.96–6.87 (m, 2H), 6.86–6.81
(m, 1H), 6.79–6.73 (m, 1H), 5.80 (d, J = 2.2
Hz, 1H). 13C NMR (DMSO-d6,
100 MHz): δ 154.1, 137.6, 137.1, 127.9, 127.0, 125.3, 123.5,
122.2, 121.6, 121.2, 119.6, 119.0, 118.7, 114.0, 112.0, 50.9. High
resolution mass spectrometry HRMS (electrospray ionization, ESI):
calcd for C18H17N4O [M + MeCN + H]+ 305.1402; found 305.1418. TLC (SiO2): Rf = 0.06 (60% EtOAc in n-pentane).

4-(5-Methoxy-2-methyl-1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4b)
Prepared following the
general procedure (A), starting from aldehyde 1b (40 mg, 191 μmol), amine 2a (29 mg, 376 μmol),
and nucleophile 3a (29 mg, 248 μmol). Yield: 52
mg (92%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 10.98 (d, J = 2.5 Hz,
1H), 9.12 (d, J = 1.9 Hz, 1H), 7.66–7.48 (m,
1H), 7.37 (m, 1H), 7.18 (d, J = 2.5 Hz, 1H), 7.11
(m 1H), 7.07 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 6.94
(ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.79 (d, J = 8.7 Hz, 1H), 6.73 (dd, J = 8.7, 2.7
Hz, 1H), 6.56 (d, J = 2.7 Hz, 1H), 5.79 (d, J = 2.3 Hz, 1H), 3.58 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): δ 153.9, 153.7, 136.7, 130.8,
124.9, 123.0, 122.9, 121.2, 119.2, 118.6, 118.2, 114.4, 112.9, 112.2,
111.6, 55.2, 50.6. HRMS (ESI): calcd for C19H19N4O2 [M + MeCN + H]+ 335.1508; found
335.1517. TLC (SiO2): Rf =
0.13 (5% MeOH in DCM).

6-Bromo-4-(1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4c)
Prepared following the
general procedure (A), starting from aldehyde 1c (40 mg, 155 μmol), amine 2a (24 mg, 311 μmol),
and nucleophile 3a (47 mg, 292 μmol). Yield: 48
mg (91%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 11.19–10.92 (m, 1H), 9.56–9.44
(m, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.35–7.31 (m, 1H), 7.28 (dd, J = 8.5, 2.3 Hz, 1H), 7.25 (d, J = 2.5
Hz, 1H), 7.13–7.05 (m, 2H), 7.00–6.93 (m, 1H), 6.81
(d, J = 8.5 Hz, 1H), 5.92–5.82 (m, 1H). 13C NMR (DMSO-d6, 100 MHz): δ
153.3, 136.7, 136.6, 130.3, 129.0, 124.7, 124.3, 123.3, 121.3, 119.0,
118.8, 117.7, 115.7, 112.0, 111.8, 50.1. HRMS (ESI): calcd for C18H16BrN4O [M + MeCN + H]+ 383.0507; found m/z 383.0516.
TLC (SiO2): Rf = 0.15 (5% MeOH
in DCM).

6-Fluoro-4-(1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4d)
Prepared following the
general procedure (A), starting from aldehyde 1d (40 mg, 203 μmol), amine 2a (31 mg, 402 μmol),
and nucleophile 4a (31 mg, 265 μmol). Yield: 50
mg (88%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 11.01 (s, 1H), 9.31 (s, 1H), 7.65–7.48
(m, 1H), 7.48–7.31 (m, 1H), 7.24 (s, 1H), 7.22–7.19
(m, 1H), 7.13–7.04 (m, 1H), 7.01–6.92 (m, 2H), 6.91–6.82
(m, 1H), 6.82–6.75 (m, 1H), 5.84 (s, 1H). 13C NMR
(DMSO-d6, 100 MHz): δ 156.4 (d, 1JCF = 236.1 Hz), 153.2, 136.3,
133.3 (d, 4JCF = 1.9 Hz), 124.3,
123.1 (d, 3JCF = 7.0 Hz), 122.8,
120.8, 118.7, 118.3, 117.1, 114.4 (d, 3JCF = 7.7 Hz), 113.9 (d, 2JCF = 22.7 Hz), 112.50 (d, 2JCF = 23.6 Hz), 111.3, 49.9. HRMS (ESI): calcd for C16H13FN4O [M + H]+ 282.1043;
found 282.1054. TLC (SiO2): Rf = 0.16 (5% MeOH in DCM).

7-Chloro-4-(1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4e)
Prepared following the
general procedure (A), starting from aldehyde 1e (40 mg, 187 μmol), amine 2a (29 mg, 376 μmol),
and nucleophile 3a (29 mg, 248 μmol). Yield: 49
mg (88%); white solid. 1H NMR (CD3OD, 400 MHz):
δ 7.41 (m, 1H), 7.35 (m, 1H), 7.19 (s, 1H), 7.09 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 6.94 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.88 (d, J = 2.0 Hz, 1H),
6.82 (dd, J = 8.3, 0.9 Hz, 1H), 6.76 (dd, J = 8.3, 2.0 Hz, 1H), 5.92 (s, 1H). 13C NMR (CD3OD, 100 MHz): δ 153.8, 139.4, 137.4, 132.3, 128.9, 125.4,
123.9, 121.8, 121.4, 121.1, 119.7, 119.3, 118.2, 113.6, 112.3, 50.7.
HRMS (ESI): calcd for C18H16ClN4O
[M + MeCN + H]+ 339.1013; found 339.1029. TLC (SiO2): Rf = 0.09 (5% MeOH in DCM).

4-(1H-Indol-3-yl)-7-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one (4f)
Prepared following the
general procedure (A), starting from aldehyde 1f (40 mg, 162 μmol), amine 2a (25 mg, 324 μmol),
and nucleophile 3a (25 mg, 213 μmol). Yield: 46
mg (86%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 11.17–10.91 (m, 1H), 9.85–9.48
(m, 1H), 7.54–7.48 (m, 1H), 7.45–7.41 (m, 1H), 7.41–7.36
(m, 1H), 7.28–7.22 (m, 1H), 7.20–7.14 (m, 2H), 7.14–7.05
(m, 2H), 6.99–6.93 (m, 1H), 5.94 (s, 1H). 13C NMR
(DMSO-d6, 100 MHz): δ 152.7, 137.5,
136.3, 127.9 (q, 2JCF = 31.8
Hz), 127.2, 125.7 (q, 4JCF =
1.2 Hz), 123.6 (q, 1JCF = 272.1
Hz), 124.3, 123.0, 120.9, 118.6, 118.4, 116.9, 115.95 (q, 3JCF = 4.5 Hz), 111.3, 109.5 (q, 3JCF = 4.2 Hz), 49.9. HRMS (ESI):
calcd for C19H16F3N4O
[M + MeCN + H]+ 373.1276; found 373.1281. TLC (SiO2): Rf = 0.15 (5% MeOH in DCM).

4-(1H-Indol-3-yl)-8-methoxy-3,4-dihydroquinazolin-2(1H)-one (4g)
Prepared following the
general procedure (A), starting from aldehyde 1g (40 mg, 191 μmol), amine 2a (29 mg, 376 μmol),
and nucleophile 3a (29 mg, 248 μmol). Yield: 45
mg (80%); white solid. 1H NMR (CDCl3/CD3OD, 400 MHz): δ 7.31–7.24 (m, 1H), 7.23–7.16
(m, 1H), 7.03 (s, 1H), 6.97–6.90 (m, 1H), 6.82–6.76
(m, 1H), 6.68–6.64 (m, 2H), 6.46–6.37 (m, 1H), 5.82
(s, 1H), 3.76 (s, 3H). 13C NMR (CDCl3/CD3OD, 100 MHz): δ 156.2, 146.5, 138.3, 126.1, 126.0, 124.2,
123.1, 122.9, 122.5, 120.0, 119.7, 117.8, 56.3, 52.5. HRMS (ESI):
calcd for C19H19N4O2 [M
+ MeCN + H]+ 335.1508; found 335.1524. TLC (SiO2): Rf = 0.16 (5% MeOH in DCM).

1-Benzyl-4-(1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4h)
Prepared following the
general procedure (A), starting from aldehyde 1h (40 mg, 149 μmol), amine 2a (23 mg, 298 μmol),
and nucleophile 3a (23 mg, 196 μmol). Yield: 45
mg (86%); white solid. 1H NMR (CDCl3, 400 MHz):
δ 8.34 (s, 1H), 7.66–7.49 (m, 1H), 7.42–7.29 (m,
6H), 7.25–7.17 (m, 1H), 7.15–7.05 (m, 3H), 6.98–6.90
(m, 1H), 6.88–6.81 (m, 2H), 6.00 (s, 1H), 5.55 (s, 1H), 5.29
(d, J = 16.6 Hz, 1H), 5.21 (d, J = 16.6 Hz, 1H). 13C NMR (CDCl3, 100 MHz):
δ 155.5, 137.8, 137.6, 137.0, 128.8, 128.3, 127.1, 126.9, 126.6,
125.4, 124.0, 123.4, 122.7, 122.4, 120.2, 119.7, 117.0, 114.3, 111.7,
51.0, 46.2. HRMS (ESI): calcd for C23H20N3O [M + MeCN + H]+ 354.1606; found 354.1606. TLC
(SiO2): Rf = 0.13 (5% MeOH
in DCM).

4-(5-Methyl-1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4i)
Prepared following the
general procedure (A), starting from aldehyde 1a (40 mg, 224 μmol), amine 2a (34 mg, 441 μmol),
and nucleophile 3b (38 mg, 290 μmol). Yield: 57
mg (92%); yellow solid. 1H NMR (DMSO-d6, 400 MHz): δ 10.87 (s, 1H), 9.29 (s, 1H), 7.36–7.33
(m, 1H), 7.31–7.26 (m, 1H), 7.20–7.17 (m, 1H), 7.16–7.10
(m, 2H), 7.01–6.87 (m, 3H), 6.84–6.78 (m, 1H), 6.10–5.68
(m, 1H), 2.35 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): δ 153.8, 137.2, 135.1, 127.5, 126.9,
126.5, 125.2, 123.2, 122.8, 121.9, 120.8, 118.8, 117.5, 113.6, 111.3,
50.5, 21.4. HRMS (ESI): calcd for C19H19N4O [M + MeCN + H]+ 319.1559; found m/z 319.1575. TLC (SiO2): Rf = 0.16 (5% MeOH in DCM).

4-(5-Bromo-1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4j)
Prepared following the
general procedure (A), starting from aldehyde 1a (40 mg, 224 μmol), amine 2a (34 mg, 441 μmol),
and nucleophile 3c (57 mg, 291 μmol). Yield: 70
mg (91%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 11.17 (br s, 1H), 9.29 (br s, 1H), 7.67
(d, J = 1.9 Hz, 1H), 7.33 (d, J =
8.6 Hz, 1H), 7.21–7.14 (m, 2H), 7.11–7.08 (m, 1H), 6.93
(d, J = 7.5 Hz, 1H), 6.85 (dd, J = 8.0, 1.2 Hz, 1H), 6.79 (ddd, J = 7.5, 7.5, 1.2
Hz, 1H), 5.80 (s, 1H). 13C NMR (DMSO-d6, 100 MHz): δ 153.7, 137.2, 135.4, 127.7, 126.7,
126.5, 124.8, 123.7, 121.5, 121.4, 121.0, 118.1, 113.7, 111.4, 50.1.
HRMS (ESI): calcd for C18H16BrN4O
[M + MeCN + H]+ 383.0507; found 383.0502. TLC (SiO2): Rf = 0.16 (5% MeOH in DCM).

4-(2-Methyl-1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4k)
Prepared following the
general procedure (A), starting from aldehyde 1a (40 mg, 224 μmol), amine 2a (34 mg, 441 μmol),
and nucleophile 3d (38 mg, 290 μmol). Yield: 58
mg (93%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 10.93 (s, 1H), 9.28 (s, 1H), 7.34–7.26
(m, 1H), 7.26–7.20 (m, 1H), 7.11 (m, 1H), 7.01–6.96
(m, 1H), 6.89–6.81 (m, 2H), 6.77–6.72 (m, 2H), 5.95
(s, 1H), 2.46 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): δ 153.7, 137.7, 135.8, 133.2, 127.9,
127.0, 126.7, 121.9, 121.2, 120.5, 118.8, 113.9, 113.7, 110.9, 49.9,
11.8. HRMS (ESI): calcd for C19H19N4O [M + MeCN + H]+ 319.1551; found 319.1559. TLC (SiO2): Rf = 0.16 (5% MeOH in DCM).

4-(2-Phenyl-1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4l)
Prepared following the
general procedure (A), starting from aldehyde 1a (40 mg, 224 μmol), amine 2a (34 mg, 441 μmol),
and nucleophile 3e (56 mg, 290 μmol). Yield: 69
mg (91%); yellow solid. 1H NMR (DMSO-d6, 400 MHz): δ 11.43 (s, 1H), 9.35 (d, J = 1.9 Hz, 1H), 7.81–7.73 (m, 2H), 7.63–7.55 (m, 2H),
7.54–7.47 (m, 1H), 7.45–7.41 (m, 1H), 7.37–7.32
(m, 1H), 7.29–7.24 (m, 1H), 7.17–7.05 (m, 2H), 6.98–6.91
(m, 1H), 6.89 (dd, J = 8.0, 1.1 Hz, 1H), 6.70 (m,
1H), 6.61–6.54 (m, 1H), 5.99 (s, 1H). 13C NMR (DMSO-d6, 100 MHz): δ 153.8, 137.6, 136.8, 136.8,
132.6, 129.3, 129.2, 128.5, 128.1, 126.7, 126.5, 122.0, 121.6, 121.3,
120.3, 119.3, 114.0, 113.5, 111.8, 50.5. HRMS (ESI): calcd for C24H21N4O [M + MeCN + H]+ 381.1715;
found 381.1730. TLC (SiO2): Rf = 0.20 (5% MeOH in DCM).

4-(5-Methoxy-1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4m)
Prepared following the
general procedure (A) starting from aldehyde 1a (40 mg, 224 μmol), amine 2a (34 mg, 441 μmol),
and nucleophile 3f (47 mg, 292 μmol). Yield: 52
mg (76%); pink solid. 1H NMR (DMSO-d6, 400 MHz): δ 10.76 (s, 1H), 9.34 (d, J = 1.9 Hz, 1H), 7.17 (d, J = 8.7 Hz, 1H), 7.15–7.09
(m, 1H), 7.01–6.96 (m, 1H), 6.90–6.85 (m, 1H), 6.81–6.74
(m, 3H), 6.65 (dd, J = 8.7, 2.5 Hz, 1H), 5.90 (d, J = 1.7 Hz, 1H), 3.64 (s, 3H), 2.43 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): δ 153.8,
153.2, 137.8, 133.8, 130.8, 127.9, 127.2, 127.1, 121.8, 121.3, 114.0,
113.8, 111.4, 109.5, 101.7, 55.5, 49.9, 11.9. HRMS (ESI): calcd for
C20H21N4O2 [M + MeCN +
H]+ 349.1665; found 349.1669. TLC (SiO2): Rf = 0.16 (5% MeOH in DCM).

Methyl 3-(2-oxo-1,2,3,4-Tetrahydroquinazolin-4-yl)-1H-indole-4-carboxylate (4n)
Prepared
following the general procedure (A), starting from aldehyde 1a (40 mg, 224 μmol), amine 2a (34 mg,
441 μmol), and nucleophile 3g (51 mg, 291 μmol).
Yield: 60 mg (83%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 11.46 (s, 1H), 9.28 (s, 1H), 7.75–7.66
(m, 2H), 7.27–7.20 (m, 1H), 7.19–7.14 (m, 1H), 7.03–6.97
(m, 1H), 6.93–6.88 (m, 1H), 6.87–6.83 (m, 1H), 6.84–6.73
(m, 2H), 6.27 (d, J = 2.5 Hz, 1H), 3.93 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): δ
168.7, 154.1, 137.8, 137.6, 127.6, 126.9, 126.4, 123.1, 122.8, 122.6,
122.3, 121.1, 120.3, 118.8, 117.0, 113.8, 52.2, 49.8. HRMS (ESI):
calcd for C18H16N3O3 [M
+ H]+ 322.1192; found 322.1202. TLC (SiO2): Rf = 0.17 (5% MeOH in DCM).

4-(1-Methyl-1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4o)24
Prepared
following the general procedure (A), starting from aldehyde 1a (40 mg, 224 μmol), amine 2a (34 mg,
441 μmol), and nucleophile 3h (38 mg, 290 μmol).
Yield: 52 mg (84%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 9.27 (d, J = 1.9
Hz, 1H), 7.56 (m, 1H), 7.40 (m, 1H), 7.21 (t, J =
2.2 Hz, 1H), 7.15 (s, 1H), 7.17–7.07 (m, 1H), 7.13–7.06
(m, 1H), 6.99 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.00–6.93
(m, 1H), 6.86 (dd, J = 8.0, 1.2 Hz, 1H), 6.78 (m,
1H), 5.82 (d, J = 2.2 Hz, 1H), 3.74 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): δ
153.7, 137.1, 127.6, 127.2, 126.5, 125.3, 121.7, 121.3, 120.8, 119.4,
118.8, 117.6, 113.7, 109.8, 50.2, 32.3. HRMS (ESI): calcd for C19H19N4O [M + MeCN + H]+ 319.1559;
found m/z 319.1567. TLC (SiO2): Rf = 0.08 (60% EtOAc in n-pentane).

4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-3,4-dihydroquinazolin-2(1H)-one (4p)
Prepared following the
general procedure (A), starting from aldehyde 1a (40 mg, 224 μmol), amine 2a (34 mg, 441 μmol),
and nucleophile 3i (34 mg, 288 μmol). Yield: 53
mg (90%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 11.53 (s, 1H), 9.31 (s, 1H), 8.19 (d, J = 4.6 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H),
7.33–7.26 (m, 2H), 7.17–7.08 (m, 1H), 7.05–6.95
(m, 2H), 6.91–6.84 (m, 1H), 6.83–6.78 (m, 1H), 6.07–5.61
(m, 1H). 13C NMR (DMSO-d6,
100 MHz): δ 153.7, 148.9, 142.7, 137.1, 127.7, 127.3, 126.6,
123.3, 121.3, 121.0, 117.2, 117.2, 115.2, 113.7, 50.5. HRMS (ESI):
calcd for C15H13N4O [M + H]+ 265.1089; found 265.1076. TLC (SiO2): Rf = 0.09 (5% MeOH in DCM).

3-Benzyl-4-(1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (6a)24
Prepared following
the general procedure (A), starting
from aldehyde 1a (40 mg, 224 μmol), amine 2b (36 mg, 336 μmol), and nucleophile 3a (34 mg, 290 μmol). Yield: 75 mg (95%); yellow solid. 1H NMR (CDCl3/CD3OD, 400 MHz): δ
11.14 (d, J = 2.5 Hz, 1H), 9.70 (s, 1H), 7.53–7.48
(m, 1H), 7.47–7.45 (m, 1H), 7.44–7.35 (m, 3H), 7.34–7.27
(m, 3H), 7.15–7.07 (m, 2H), 7.04–6.94 (m, 2H), 6.92
(dd, J = 8.0, 1.1 Hz, 1H), 6.78 (m, 1H), 5.75 (s,
1H), 5.17 (d, J = 15.5 Hz, 1H), 3.77 (d, J = 15.4 Hz, 1H). 13C NMR (CDCl3/CD3OD, 100 MHz): δ 155.8, 138.5, 138.3, 136.6, 129.5, 128.9,
128.7, 128.3, 128.1, 126.1, 124.7, 123.0, 122.8, 122.5, 120.3, 119.9,
117.0, 114.7, 112.6, 56.5, 47.8. HRMS (ESI): calcd for C23H20N3O [M + H]+ 354.1606; found
354.1613. TLC (SiO2): Rf =
0.20 (40% EtOAc in n-pentane).

4-(1H-Indol-3-yl)-3-(thiophen-2-ylmethyl)-3,4-dihydroquinazolin-2(1H)-one (6b)
Prepared following the
general procedure (A), starting from aldehyde 1a (40 mg, 224 μmol), amine 2c (33 mg, 292 μmol),
and nucleophile 3a (34 mg, 290 μmol). Yield: 76
mg (94%); white solid. 1H NMR (CDCl3/CD3OD, 400 MHz): δ 7.44 (m, 1H), 7.38 (m, 1H), 7.35 (s,
1H), 7.31 (dd, J = 4.8, 1.6 Hz, 1H), 7.14–7.07
(m, 2H), 6.99–6.95 (m, 2H), 6.95–6.91 (m, 1H), 6.91–6.86
(m, 2H), 6.79 (m, 1H), 5.86 (s, 1H), 5.29 (dd, J =
15.5, 0.9 Hz, 1H), 4.07 (d, J = 15.5 Hz, 1H). 13C NMR (CDCl3/CD3OD, 100 MHz): δ
156.1, 141.8, 139.4, 137.3, 129.8, 129.1, 128.7, 128.4, 127.2, 127.1,
126.0, 123.9, 123.8, 123.3, 121.3, 120.9, 117.5, 115.6, 113.6, 57.1,
43.7. HRMS (ESI): calcd for C21H18N3OS [M + H]+ 360.1171; found 360.1168. TLC (SiO2): Rf = 0.16 (5% MeOH in DCM).

3-Benzyl-4-(2,4-dimethoxyphenyl)-3,4-dihydroquinazolin-2(1H)-one (6c)
Prepared following the
general procedure (A) but with 30 min of heating in the
second step, starting from aldehyde 1a (40 mg, 224 μmol),
amine 2b (36 mg, 336 μmol), and nucleophile 5a (40 mg, 289 μmol). Yield: 72 mg (86%); yellow solid. 1H NMR (CDCl3, 400 MHz): δ 8.96 (s, 1H), 7.51
(m, 5H), 7.45–7.40 (m, 1H), 7.30 (m, 1H), 7.22–7.15
(m, 1H), 7.08–6.93 (m, 2H), 6.77–6.57 (m, 2H), 6.05
(s, 1H), 5.62 (d, J = 15.1 Hz, 1H), 4.01 (s, 6H),
3.93 (d, J = 15.1 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): δ 160.1, 157.0, 153.4, 137.8,
136.4, 128.4, 127.9, 127.7, 127.4, 127.1, 125.9, 122.9, 121.6, 121.1,
113.6, 105.7, 98.6, 55.6, 55.2, 54.6, 46.8. HRMS (ESI): calcd for
C23H23N2O3 [M + H]+ 375.1709; found 375.1711. TLC (SiO2): Rf = 0.26 (40% EtOAc in n-pentane).

4-(2,4-Dimethoxyphenyl)-3,4-dihydroquinazolin-2(1H)-one (6d)
Prepared following the general procedure
(A) but with 30 min of heating in the second step, starting
from aldehyde 1a (40 mg, 224 μmol), amine 2a (34 mg, 441 μmol), and nucleophile 5a (40 mg, 289 μmol). Yield: 35 mg (55%); white solid. 1H NMR (DMSO-d6, 400 MHz,): δ 9.21
(s, 1H), 7.17–7.07 (m, 1H), 7.05–6.95 (m, 3H), 6.86–6.79
(m, 2H), 6.64–6.59 (m, 1H), 6.54–6.48 (m, 1H), 5.80
(d, J = 2.4 Hz, 1H), 3.86 (s, 3H), 3.76 (s, 3H). 13C NMR (DMSO-d6, 400 MHz,): δ
159.4, 156.2, 153.6, 136.7, 127.3, 127.2, 125.8, 124.9, 121.2, 120.6,
113.3, 104.6, 98.1, 55.2, 54.8, 50.2. HRMS (ESI): calcd for C18H20N3O3 [M + MeCN + H]+ 326.1505; found 326.1508. TLC (SiO2): Rf = 0.21 (5% MeOH in DCM).

4-(2,4-Dimethoxyphenyl)-3-(1-methylpiperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (6e)
Prepared following the
general procedure (A) but with 30 min of heating the
second step, starting from aldehyde 1a (40 mg, 224 μmol),
amine 2d (33 mg, 289 μmol), and nucleophile 5a (68 mg, 492 μmol). Yield: 43 mg (50%); white solid. 1H NMR (CDCl3, 400 MHz): δ 7.47 (s, 1H), 7.24–7.20
(m, 2H), 7.08–6.96 (m, 1H), 6.86–6.76 (m, 1H), 6.65–6.58
(m, 1H), 6.40–6.31 (m, 1H), 6.29 (dd, J =
8.5, 2.4 Hz, 1H), 5.95 (s, 1H), 4.41–4.14 (m, 1H), 3.84 (s,
3H), 3.67 (s, 3H), 2.95 (d, J = 10.7 Hz, 1H), 2.79
(d, J = 11.7 Hz, 1H), 2.24 (s, 3H), 2.21–1.97
(m, 4H), 1.59 (d, J = 12.1 Hz, 1H), 1.45 (m, 2H). 13C NMR (CDCl3, 100 MHz): δ 160.0, 155.3,
154.9, 135.0, 127.5, 127.0, 125.3, 125.0, 123.2, 121.8, 113.3, 104.4,
98.2, 55.2, 55.0, 54.9, 54.8, 52.2, 51.4, 45.2, 29.4, 28.7, 21.8.
HRMS (ESI): calcd for C22H28N3O3 [M + H]+ 382.2131; found 382.2132. TLC (SiO2): Rf = 0.23 (10% MeOH in DCM).

4-(4-Hydroxy-2-methylphenyl)-3,4-dihydroquinazolin-2(1H)-one (6f)
Prepared following the
general procedure (A) but with 30 min in heating the
second step, starting from aldehyde 1a (40 mg, 224 μmol),
amine 2a (33 mg, μmol), and nucleophile 5b (31 mg, 289 μmol). Yield: 30 mg (52%); white solid. 1H NMR (DMSO-d6, 400 MHz): δ 9.62
(s, 1H), 9.15 (s, 1H), 7.07 (t, J = 7.9 Hz, 2H),
6.95 (s, 1H), 6.89 (d, J = 7.8 Hz, 1H), 6.81–6.74
(m, 2H), 6.63 (s, 1H), 6.55 (d, J = 7.8 Hz, 1H),
5.79 (d, J = 2.3 Hz, 1H), 2.17 (s, 3H). 13C NMR (DMSO-d6, 100 MHz): δ 154.0,
153.4, 137.5, 137.0, 128.5, 127.5, 126.9, 126.3, 121.9, 120.9, 119.9,
115.9, 113.6, 50.7, 20.7. HRMS (ESI): calcd for C15H15N2O2 [M + H]+ 255.1143;
found 255.1134. TLC (SiO2): Rf = 0.22 (5% MeOH in DCM).

4-(1H-Indol-3-yl)-3-(3-methoxyphenethyl)-3,4-dihydroquinazolin-2(1H)-one (7a)
Prepared following the
general procedure (B), starting from aldehyde 1a (40 mg, 224 μmol), amine 2e (43 mg, 290 μmol),
and nucleophile 3a (39 mg, 334 μmol). Yield: 82
mg (92%); off-white solid. 1H NMR (CDCl3, 400
MHz): δ 8.33–8.20 (m, 1H), 7.99 (s, 1H), 7.56 (m, 1H),
7.34 (m, 1H), 7.20–7.13 (m, 3H), 7.13–7.04 (m, 2H),
6.91–6.86 (m, 1H), 6.79 (ddd, J = 14.3, 7.7,
1.1 Hz, 2H), 6.74 (dd, J = 7.9, 2.1 Hz, 2H), 6.67–6.63
(m, 1H), 5.59 (s, 1H), 4.01 (ddd, J = 14.0, 9.0,
5.0 Hz, 1H), 3.66 (s, 3H), 3.22 (ddd, J = 13.8, 8.7,
7.1 Hz, 1H), 2.95 (ddd, J = 13.2, 9.0, 7.1 Hz, 1H),
2.71 (ddd, J = 13.4, 8.6, 5.0 Hz, 1H). δ 13C NMR (CDCl3, 100 MHz): δ 159.7, 154.1,
141.3, 136.7, 135.7, 129.6, 128.2, 126.8, 125.4, 122.8, 122.6, 122.1,
121.6, 121.3, 120.3, 119.4, 117.5, 114.3, 113.8, 112.2, 111.6, 56.9,
55.2, 47.3, 34.6. HRMS (ESI): calcd for [M + H]+ 398.1869;
found 398.1873. TLC (SiO2): Rf = 0.13 (50% EtOAc in n-pentane).

3-(3,4-Dimethoxyphenethyl)-4-(1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (7b)
Prepared following the
general procedure (B), starting from aldehyde 1a (40 mg, 224 μmol), amine 2f (53 mg, 290 μmol),
and nucleophile 3a (39 mg, 334 μmol). Yield: 85
mg (90%); white solid. 1H NMR (CDCl3/CD3OD, 400 MHz): δ 7.33–7.24 (m, 2H), 7.21–7.13
(m, 1H), 7.03–6.95 (m, 1H), 6.96–6.87 (m, 2H), 6.85–6.76
(m, 1H), 6.71–6.53 (m, 4H), 6.50–6.36 (m, 2H), 5.40
(s, 1H), 3.70–3.56 (m, 4H), 3.47 (s, 3H), 3.07–2.87
(m, 1H), 2.73–2.61 (m, 1H), 2.52–2.37 (m, 1H). 13C NMR (CDCl3/CD3OD, 100 MHz): δ
154.6, 148.9, 147.6, 137.1, 135.4, 132.4, 128.2, 127.0, 125.4, 123.6,
122.5, 122.2, 121.8, 121.0, 119.8, 119.0, 116.5, 113.9, 112.3, 111.9,
111.7, 57.2, 56.0, 55.7, 47.6, 33.9. HRMS (ESI): calcd for C26H26N3O3 [M + H]+ 428.1974;
found 428.1977. TLC (SiO2): Rf = 0.10 (50% EtOAc in n-pentane).

4-(1H-Indol-3-yl)-3-(2-(thiophen-2-yl)ethyl)-3,4-dihydroquinazolin-2(1H)-one (7c)
Prepared following the
general procedure (B), starting from aldehyde 1a (40 mg, 224 μmol), amine 2g (37 mg, 290 μmol),
and nucleophile 3a (39 mg, 334 μmol). Yield: 80
mg (96%); light yellow solid. 1H NMR (CDCl3,
400 MHz): δ 8.32–8.24 (m, 1H), 8.15 (s, 1H), 7.58 (m,
1H), 7.35 (m, 1H), 7.21–7.13 (m, 2H), 7.14–7.03 (m,
3H), 6.94–6.85 (m, 2H), 6.83–6.70 (m, 3H), 5.67 (s,
1H), 4.01 (ddd, J = 13.3, 8.4, 5.2 Hz, 1H), 3.34–3.15
(m, 2H), 3.00–2.84 (m, 1H). 13C NMR (CDCl3, 100 MHz): δ 154.1, 141.8, 136.7, 135.6, 128.2, 127.1, 126.8,
125.4, 125.3, 123.8, 122.9, 122.7, 122.2, 121.5, 120.4, 119.4, 117.5,
113.9, 111.6, 57.2, 47.5, 28.5. HRMS (ESI): calcd for C22H29N3OS [M + H]+ 374.1327; found
374.1324. TLC (SiO2): Rf =
0.15 (50% EtOAc in pentane).

3-(But-3-en-1-yl)-4-(1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (7d)
Prepared following the
general procedure (B), starting from aldehyde 1a (40 mg, 224 μmol), amine 2h (21 mg, 290 μmol),
and nucleophile 3a (39 mg, 334 μmol). Yield: 68
mg (96%); off-white solid. 1H NMR (CDCl3, 400
MHz): δ 8.32 (s, 1H), 8.05 (s, 1H), 7.63 (dd, J = 7.9, 1.1 Hz, 1H), 7.35 (m, 1H), 7.22–7.14 (m, 2H), 7.09
(m, 2H), 7.01 (ddd, J = 7.7, 1.5, 0.7 Hz, 1H), 6.85–6.72
(m, 2H), 5.88 (s, 1H), 5.78 (m, 1H), 5.15–4.88 (m, 2H), 3.91
(ddd, J = 13.9, 8.7, 6.4 Hz, 1H), 3.04 (ddd, J = 14.2, 8.6, 5.9 Hz, 1H), 2.47–2.35 (m, 1H), 2.33–2.20
(m, 1H). 13C NMR (CDCl3, 100 MHz): δ 154.2,
136.7, 135.7, 135.6, 128.2, 126.8, 125.4, 122.7, 122.6, 122.1, 121.5,
120.3, 119.4, 117.6, 116.7, 113.9, 111.6, 56.4, 44.7, 32.2. HRMS (ESI):
calcd for [M + H]+ 318.1606; found 318.1606. TLC (SiO2): Rf = 0.2 (50% EtOAc in n-pentane).

3-((1H-Indol-4-yl)methyl)-4-(1H-indol-3-yl)-3,4-dihydroquinazolin-2(1H)-one (7e)
Prepared following the general procedure
(B), starting from aldehyde 1a (40 mg, 224
μmol),
amine 2i (42 mg, 290 μmol), and nucleophile 3a (39 mg, 334 μmol). Yield: 32 mg (36%); off-white
solid. 1H NMR (DMSO-d6, 400
MHz): δ 11.13 (d, J = 13.2 Hz, 2H), 9.66 (s,
1H), 8.28 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.42–7.23
(m, 4H), 7.05 (m, 3H), 6.90 (m, 4H), 6.68 (m, 1H), 6.45 (s, 1H), 5.60
(s, 1H), 5.50 (d, J = 15.0 Hz, 1H), 3.83 (d, J = 15.0 Hz, 2H). 13C NMR (DMSO-d6, 100 MHz): δ 152.9, 137.1, 136.3, 136.2, 128.4,
127.8, 127.1, 126.7, 125.3, 124.7, 124.0, 121.6, 121.3, 121.2, 121.0,
119.2, 119.0, 118.5, 116.3, 113.6, 112.1, 111.0, 99.8, 54.6, 44.7.
HRMS (ESI): calcd for [M + H]+ 393.1715; found 393.1729.
TLC (SiO2): Rf = 0.1 (50% EtOAc
in n-pentane).

Supporting Information Available
The Supporting Information
is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b02298.Copies of 1H and 13C NMR spectra
for all compounds (PDF)



Supplementary Material
ao8b02298_si_001.pdf

 Author Present Address
‡ Department of Radiology, Stanford University, Stanford, California
94306, United States (M.Y.S.).

Author Present Address
† Beactica
AB, Uppsala Business Park, Virdings allé 2, 75450
Uppsala, Sweden (R.T.S.).

The authors
declare no competing financial interest.

Acknowledgments
This research
was supported by Uppsala University. The authors
thank Dr Lisa Haigh (Imperial College London) for assistance with
HRMS determination.
==== Refs
References
Speckamp W. N. ; Moolenaar M. J. 
New Developments
in the Chemistry of N -Acyliminium
Ions and Related Intermediates . Tetrahedron 
2000 , 56 , 3817 –3856 . 10.1016/S0040-4020(00)00159-9 .
Maryanoff B. E. ; Zhang H. ; Cohen J. H. ; Turchi I. J. ; Maryanoff C. A. 
Cyclizations
of N -Acyliminium Ions . Chem. Rev. 
2004 , 104 , 1431 –1628 . 10.1021/cr0306182 .15008627 
Yazici A. ; Pyne S. 
Intermolecular Addition Reactions of N-Acyliminium Ions (Part I)1 . Synthesis 
2009 , 339 –368 . 10.1055/s-0028-1083325 .
Yazici A. ; Pyne S. 
Intermolecular Addition
Reactions of N-Acyliminium Ions (Part II)1 . Synthesis 
2009 , 513 –541 . 10.1055/s-0028-1083346 .
Wu P. ; Nielsen T. E. 
Scaffold Diversity
from N -Acyliminium
Ions . Chem. Rev. 
2017 , 117 , 7811 –7856 . 10.1021/acs.chemrev.6b00806 .28493667 
Marson C. 
Synthesis
via N-Acyliminium Cyclisations of N-Heterocyclic
Ring Systems Related to Alkaloids . Arkivoc 
2001 , 1 , 1 –16 . 10.3998/ark.5550190.0002.101 .
Nash A. ; Qi X. ; Maity P. ; Owens K. ; Tambar U. K. 
Development of the
Vinylogous Pictet-Spengler Cyclization and Total Synthesis of (±)-Lundurine
A . Angew. Chem., Int. Ed. 
2018 , 57 , 6888 –6891 . 10.1002/anie.201803702 .
Das M. ; Saikia A. K. 
Stereoselective Synthesis of Pyrroloisoindolone and
Pyridoisoindolone via Aza-Prins Cyclization of Endocyclic N -Acyliminium Ions . J. Org. Chem. 
2018 , 83 , 6178 –6185 . 10.1021/acs.joc.8b00440 .29715018 
Mari G. ; De Crescentini L. ; Mantellini F. ; Santeusanio S. ; Favi G. 
5-Methylene N -Acyl
Dihydropyridazinium Ions as
Novel Mannich-Type Acceptors in 1,4 Additions of Nucleophiles . Org. Chem. Front. 
2018 , 5 , 1308 –1311 . 10.1039/C8QO00032H .
Maury J. ; Force G. ; Darses B. ; Lebœuf D. 
Boron Trifluoride-Mediated
Trifluoromethylthiolation of N-Acyliminiums . Adv. Synth. Catal. 
2018 , 360 , 2752 –2756 . 10.1002/adsc.201800514 .
Berthet M. ; Beauseigneur A. ; Moine C. ; Taillier C. ; Othman M. ; Dalla V. 
Novel Hybrid Prins/Aza-Prins Oxocarbenium/N-Acyliminium Cascade: Expedient Access to Complex Indolizidines . Chem. - Eur. J. 
2018 , 24 , 1278 –1282 . 10.1002/chem.201705949 .29265547 
Hasegawa H. ; Muraoka M. ; Matsui K. ; Kojima A. 
Discovery of a Novel
Potent Na+/Ca2+ Exchanger Inhibitor: Design,
Synthesis and Structure-Activity Relationships of 3,4-Dihydro-2(1H)-Quinazolinone
Derivatives . Bioorg. Med. Chem. Lett. 
2003 , 13 , 3471 –3475 . 10.1016/S0960-894X(03)00744-3 .14505651 
Hasegawa H. ; Muraoka M. ; Matsui K. ; Kojima A. 
A Novel Class of Sodium/calcium
Exchanger Inhibitors: Design, Synthesis, and Structure-Activity Relationships
of 4-Phenyl-3-(Piperidin-4-Yl)-3,4-Dihydro-2(1H)-Quinazolinone Derivatives . Bioorg. Med. Chem. Lett. 
2006 , 16 , 727 –730 . 10.1016/j.bmcl.2005.10.012 .16249082 
Hasegawa H. ; Muraoka M. ; Ohmori M. ; Matsui K. ; Kojima A. 
A Novel Class
of Sodium/calcium Exchanger Inhibitor: Design, Synthesis, and Structure-Activity
Relationships of 3,4-Dihydro-2(1H)-Quinazolinone Derivatives . Bioorg. Med. Chem. 
2005 , 13 , 3721 –3735 . 10.1016/j.bmc.2005.03.019 .15863001 
Coombs R. V. ; Danna R. P. ; Denzer M. ; Hardtmann G. E. ; Huegi B. ; Koletar G. ; Koletar J. ; Ott H. ; Jukniewicz E. ; et al. Synthesis and Antiinflammatory Activity of
1-Alkyl-4-Aryl-2(1H)-Quinazolines and Quinazolinethiones . J. Med. Chem. 
1973 , 16 , 1237 –1245 . 10.1021/jm00269a006 .4747965 
Clissold S. P. ; Beresford R. 
Proquazone. A review of its pharmacodynamic and pharmacokinetic
properties, and therapeutic efficacy in rheumatic diseases and pain
states . Drugs 
1987 , 33 , 478 –502 . 10.2165/00003495-198733050-00004 .3297621 
Barrow J. C. ; Rittle K. E. ; Reger T. S. ; Yang Z.-Q. ; Bondiskey P. ; McGaughey G. B. ; Bock M. G. ; Hartman G. D. ; Tang C. ; Ballard J. ; Kuo Y. ; Prueksaritanont T. ; Nuss C. E. ; Doran S. M. ; Fox S. V. ; Garson S. L. ; Kraus R. L. ; Li Y. ; Marino M. J. ; Graufelds V. K. ; Uebele V. N. ; Renger J. J. 
Discovery
of 4,4-Disubstituted Quinazolin-2-Ones
as T-Type Calcium Channel Antagonists . ACS Med.
Chem. Lett. 
2010 , 1 , 75 –79 . 10.1021/ml100004r .24900180 
Schlegel K.-A. S. ; Yang Z.-Q. ; Reger T. S. ; Shu Y. ; Cube R. ; Rittle K. E. ; Bondiskey P. ; Bock M. G. ; Hartman G. D. ; Tang C. ; Ballard J. ; Kuo Y. ; Prueksaritanont T. ; Nuss C. E. ; Doran S. M. ; Fox S. V. ; Garson S. L. ; Kraus R. L. ; Li Y. ; Uebele V. N. ; Renger J. J. ; Barrow J. C. 
Discovery and Expanded
SAR of 4,4-Disubstituted Quinazolin-2-Ones
as Potent T-Type Calcium Channel Antagonists . Bioorg. Med. Chem. Lett. 
2010 , 20 , 5147 –5152 . 10.1016/j.bmcl.2010.07.010 .20673719 
Corbett J. W. ; Ko S. S. ; Rodgers J. D. ; Gearhart L. A. ; Magnus N. A. ; Bacheler L. T. ; Diamond S. ; Jeffrey S. ; Klabe R. M. ; Cordova B. C. ; Garber S. ; Logue K. ; Trainor G. L. ; Anderson P. S. ; Erickson-Viitanen S.
K. 
Inhibition of Clinically
Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside
Reverse Transcriptase Inhibitors . J. Med. Chem. 
2000 , 43 , 2019 –2030 . 10.1021/jm990580e .10821714 
Tucker T. J. ; Lyle T. A. ; Wiscount C. M. ; Britcher S. F. ; Young S. D. ; Sanders W. M. ; Lumma W. C. ; Goldman M. E. ; O’Brien J. A. 
Synthesis
of a Series of 4-(Arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones
as Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors . J. Med. Chem. 
1994 , 37 , 2437 –2444 . 10.1021/jm00041a023 .7520079 
Tiwari A. K. ; Mishra aK ; Bajpai A. ; Mishra P. ; Sharma R. K. ; Pandey V. K. ; Singh V. K. 
Synthesis and Pharmacological Study
of Novel Pyrido-Quinazolone Analogues as Anti-Fungal, Antibacterial,
and Anticancer Agents . Bioorg. Med. Chem. Lett. 
2006 , 16 , 4581 –4585 . 10.1016/j.bmcl.2006.06.015 .16806924 
Zhang K. F. ; Nie J. ; Guo R. ; Zheng Y. ; Ma J. A. 
Chiral Phosphoric
Acid-Catalyzed Asymmetric Aza-Friedel-Crafts Reaction of Indoles with
Cyclic N-Acylketimines: Enantioselective Synthesis of Trifluoromethyldihydroquinazolines . Adv. Synth. Catal. 
2013 , 355 , 3497 –3502 . 10.1002/adsc.201300534 .
Zhou D. ; Huang Z. ; Yu X. ; Wang Y. ; Li J. ; Wang W. ; Xie H. 
A Quinine-Squaramide Catalyzed Enantioselective
Aza-Friedel–Crafts Reaction of Cyclic Trifluoromethyl Ketimines
with Naphthols and Electron-Rich Phenols . Org.
Lett. 
2015 , 17 , 5554 –5557 . 10.1021/acs.orglett.5b02668 .26524623 
Ramana D. V. ; Vinayak B. ; Dileepkumar V. ; Murty U. S. N. ; Chowhan L. R. ; Chandrasekharam M. 
Hydrophobically
Directed, Catalyst-Free, Multi-Component
Synthesis of Functionalized 3,4-Dihydroquinazolin-2(1H)-Ones . RSC Adv. 
2016 , 6 , 21789 –21794 . 10.1039/C6RA00381H .
Stevens M. Y. ; Wieckowski K. ; Wu P. ; Sawant R. T. ; Odell L. R. 
A Microwave-Assisted
Multicomponent Synthesis of Substituted 3,4-Dihydroquinazolinones . Org. Biomol. Chem. 
2015 , 13 , 2044 –2054 . 10.1039/C4OB02417F .25518892 
Sawant R.
T. ; Stevens M. Y. ; Odell L. R. 
Rapid Access to Polyfunctionalized
3,4-Dihydroquinazolinones through a Sequential N-Acyliminium
Ion Mannich Reaction Cascade . Eur. J. Org. Chem. 
2015 , 7743 –7755 . 10.1002/ejoc.201501178 .
Sawant R. T. ; Stevens M. Y. ; Sköld C. ; Odell L. R. 
Microwave-Assisted
Branching Cascades: A Route to Diverse 3,4-Dihydroquinazolinone-Embedded
Polyheterocyclic Scaffolds . Org. Lett. 
2016 , 18 , 5392 –5395 . 10.1021/acs.orglett.6b02774 .27726402 
Sawant R. T. ; Stevens M. Y. ; Odell L. R. 
Acetic
Acid-Promoted Cascade N-Acyliminium Ion/aza-Prins
Cyclization: Stereoselective
Synthesis of Functionalized Fused Tricyclic Piperidines . Chem. Commun. 
2017 , 53 , 2110 –2113 . 10.1039/C6CC09805C .
Sawant R.
T. ; Stevens M. Y. ; Odell L. R. 
3,4-Dihydro-3-(2-Hydroxyethyl)-4-(Nitromethyl)quinazolin-2(1H)-One . Molbank 
2015 , M86610.3390/M866 .

